BCG Hsp70-CD123 Immunoconjugate Targets Childhood AML

The BCG Hsp70-CD123 immunoconjugate represents a targeted immunotherapy approach for pediatric acute myeloid leukemia, as reported in Pediatric Research. Engineered by fusing Bacillus Calmette-Guérin (BCG) heat shock protein 70 with an anti-CD123 antibody, the conjugate seeks out cells that overexpress CD123, a marker common on leukemia stem cells. In preclinical models, the conjugate binds CD123-expressing cells and triggers apoptosis, reducing leukemic burden and potentially addressing minimal residual disease. CD123 is the interleukin-3 receptor alpha chain found preferentially on malignant cells, with limited expression on normal hematopoietic stem cells, supporting targeted therapy. The BCG-derived Hsp70 component serves as an immunostimulatory signal to boost innate immune activation within the tumor microenvironment.